Most studies analyzing serum levels of MINDIN in a prostate cancer context have reported increased concentrations of MINDIN in the serum of prostate cancer patients compared with healthy subjects [15,16,17,48]. The gene discussed is SPON2; the disease is prostate carcinoma.